News

Published on 26 Nov 2024 on Benzinga

This Goldman Sachs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For...

Article preview image

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Considering buying GS stock? Here’s what analysts think:

Read the rest of the article
NYSE.TGT price evolution
NASDAQ.SAVA price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Amazon, Tesla, Rivian, Palantir And How Dogecoin Helped Low-Income Families...

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a...

Benzinga 30 Nov 2024
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study

Aβ is a protein that is said to be the primary cause of the cognitive decline associated with...

Zacks · via Yahoo Finance 26 Nov 2024
This Goldman Sachs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all ana...

Benzinga 26 Nov 2024
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava...

Cassava Sciences (SAVA) has become technically an oversold stock now, which implies exhaustion of...

Zacks · via Yahoo Finance 26 Nov 2024
United States shares higher at close of trade; Dow Jones Industrial Average up...

United States shares higher at close of trade; Dow Jones Industrial Average up 0.99%

Investing.com 25 Nov 2024
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.99% By...

U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.99%

Investing.com 25 Nov 2024
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study,...

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data...

Benzinga · via Yahoo Finance 25 Nov 2024
SAVA Stock Touches 52-Week Low at $3.95 Amid Market Volatility By Investing.com

Despite the recent downturn, Cassava Sciences has experienced a notable 1-year change, with its...

Investing.com 25 Nov 2024
Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companie...

Zacks · via Yahoo Finance 15 Nov 2024
Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge

We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch....

Insider Monkey · via Yahoo Finance 18 Oct 2024

Copyright Statfolio @ 2024

Social Accounts